Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio is a helpful tool for the prediction and diagnosis of preeclampsia (PE). Current data even show that the ratio has the potential to predict adverse pregnancy outcomes (APO) caused by placental pathologies. The aim of this article is to give a brief overview of recent findings on APO predictions based on the sFlt-1/PlGF ratio. The focus is on obstetric pathologies related to placental dysfunction (PD) such as PE and/or fetal growth restriction (FGR). New uses of the sFlt-1/PlGF ratio as a predictor of APO demonstrate its potential with regard to planning hospitalization and corticosteroid administration and the optimal timing of delivery. However, prospective interventional studies are warranted to define the exact role of the sFlt-1/PlGF ratio as a predictor of adverse pregnancy outcomes caused by placental pathologies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354351 | PMC |
| http://dx.doi.org/10.1055/a-1403-2576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting first-trimester pregnancy outcome in threatened miscarriage: A comparison of a multivariate logistic regression and machine learning models.
Radiography (Lond)
September 2025
Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Malta. Electronic address:
Introduction: Threatened miscarriage (TM), defined as first-trimester vaginal bleeding with a closed cervix and detectable fetal cardiac activity, affects up to 30 % of clinically recognised pregnancies and is linked to increased risk of adverse outcomes. This study evaluates the predictive value of first-trimester ultrasound (US) and biochemical (BC) markers in determining outcomes among women with TM symptoms.
Methods: This prospective cohort study recruited 118 women with viable singleton pregnancies (5 to 12 weeks' gestation) from Malta's national public hospital between January 2023 and June 2024.
Application of Serum sFlt-1/PlGF Ratio Combined with Uterine Artery Blood Flow Ultrasound in Predicting Early-Onset Preeclampsia.
Int J Womens Health
August 2025
Obstetrics Department, the Second Affiliated Hospital of Shandong First Medical University, Tai 'an, Shandong, 271000, People's Republic of China.
Objective: This study aimed to evaluate the predictive efficacy of combining serum soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PlGF) ratio with uterine artery Doppler ultrasound for early-onset preeclampsia (PE) before 34 weeks' gestation.
Methods: A retrospective cohort analysis was conducted on 148 singleton pregnancies (control group: n = 76; early-onset PE group: n = 72) who delivered at our institution between July 2023 and June 2024. At 24-28 weeks, serum sFlt-1 and PlGF levels were quantified via electrochemiluminescence immunoassay (Roche Elecsys), and uterine artery pulsatility index (PI), resistance index (RI), and systolic/diastolic ratio (S/D) were measured by Doppler ultrasound (M22 system, standardized settings).
sFlt-1/PlGF ratio predicts serious outcomes in early-onset fetal growth restriction.
Fetal Diagn Ther
August 2025
Introduction: This study aimed to identify a cutoff value for the soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio to predict adverse outcomes in early-onset fetal growth restriction (FGR).
Methods: In this single-center, non-blinded, retrospective cohort study, maternal serum sFlt-1/PlGF ratios were measured at the time of early-onset FGR diagnosis (<34 weeks) using Roche Elecsys® assays. The optimal cutoff for predicting severe adverse outcomes within 2 weeks was determined using receiver operating characteristic analysis.
Comparing angiogenic biomarkers and clinical history of hypertensive disease of pregnancy with the association of hypertension up to 15 years after delivery.
medRxiv
July 2025
Division of Maternal Fetal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Objective: We investigated the independent and comparative association of a history of hypertensive disease of pregnancy and elevated serum soluble fms-like tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF) ratio during the second half of pregnancy with the development of HTN up to 15 years after delivery.
Study Design: N=1,238 singleton pregnancies were part of a prospective birth cohort study that enrolled patients from 2006-2008. Serum sFlt-1/PlGF was collected at a median of 26.
Predictive accuracy of sFlt-1/PlGF ratio for preeclampsia and adverse outcomes: prospective, multicenter including primary, secondary, and tertiary care institutions, observational study in Japan.
Hypertens Res
August 2025
Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Obstetric care in Japan is organized in 3 levels and half of all deliveries are conducted at primary facilities without neonatal intensive care unit. We evaluated the predictive accuracy of the sFlt-1/PlGF ratio for the onset of preeclampsia and adverse outcomes in pregnant women with suspected preeclampsia at multiple facilities in Japan, including primary facilities. 356 pregnant women from 18 + 0 to 36 + 6 weeks of pregnancy were enrolled.
View Article and Find Full Text PDF